

AMENDMENTS TO THE CLAIMS

1. (Original) A polypeptide, derivative or analogue thereof, comprising a tandem repeat of apolipoprotein B or a truncation thereof, characterised in that the tandem repeat or truncation thereof is derived from an HSPG receptor binding region of apolipoprotein B.
2. (Original) The polypeptide, derivative or analogue thereof according to claim 1, wherein the polypeptide, derivative or analogue thereof comprises a tandem repeat which is derived from an apolipoprotein B LDL receptor binding domain cluster B.
3. (Original) The polypeptide, derivative or analogue thereof according to claim 1 comprising a tandem repeat of apoB3359-3367 or a truncation thereof.
4. (Original) The polypeptide, derivative or analogue thereof according to claim 1 comprising the amino acid sequence of SEQ ID No. 1
5. (Previously Presented) The polypeptide, derivative or analogue thereof according to claim 3, wherein at least one of the first, second, third, seventh, eighth, ninth, tenth, eleventh, twelfth, sixteenth, seventeenth or eighteenth residues is substituted or deleted.
6. (Previously Presented) The polypeptide according to claim 1 of formula:
abcRKRxyza'b'c'RKRx'y'z' (I)
wherein
a and a' are each independently selected from the group consisting of a positively charged residue, which may be Arginine (R), Lysine (K) or Histidine (H), Leucine (L), Tryptophan (W), and deleted;
b and b' are each independently selected from the group consisting of Leucine (L), Arginine (R), Lysine (K), and deleted;

c and c' are each independently selected from the group consisting of Threonine (T), Tryptophan (W), and a positively charged residue, which may be Arginine (R), Lysine (K) or Histidine (H);

x and x' are each independently selected from the group consisting of Glycine (G), Tryptophan (W), Leucine (L), and a positively charged residue, which may be Arginine (R), Lysine (K) or Histidine (H);

y and y' are each independently selected from the group consisting of Leucine (L), a positively charged residue, which may be Arginine (R), Lysine (K) or Histidine (H), and deleted; and

z and z' are each independently selected from the group consisting of a positively charged residue, which may be Arginine (R), Lysine (K) or Histidine (H), Leucine, and deleted.

7. (Previously Presented) The polypeptide, derivative or analogue thereof according to claim 1 comprising the amino acid sequence:
LRTRKRGRKLRTRKRGRK (SEQ ID No.2); RTRKRGRKRTRKRGRK (SEQ ID No.3); RTRKRGRRTRKRGR (SEQ ID No.4); LRKRKRLLRKRKRL (SEQ ID No.5); LRKRKRLRKLKRKRLRK (SEQ ID No.6);
WRWRKRWRKWRWRKRWRK (SEQ ID No.7); RRWRKRWRKWRWRKRWRK (SEQ ID No.34); KRWRKRWRKWRWRKRWRK (SEQ ID No.35);
LRWRKRWRKWRWRKRWRK (SEQ ID No.36); HRWRKRWRKWRWRKRWRK (SEQ ID No.37); RWRKRWRKWRWRKRWRK (SEQ ID No.38);
RRWRKRWRKRRWRKRWRK (SEQ ID No.39); KRWRKRWRKRRWRKRWRK (SEQ ID No.40); LRWRKRWRKLRWRKRWRK (SEQ ID No.41);
HRWRKRWRKHRWRKRWRK (SEQ ID No.42); RWRKRWRKRRWRKRWRK (SEQ ID No.43); RWRKRGRKRWRKRGRK (SEQ ID No.44);
RTRKRWRKRTRKRGRK (SEQ ID No.45); RWRKRWRKRRWRKRWRK (SEQ ID No.46); or RWRKRWRWRKRWRWRKRW (SEQ ID No.47).
8. (Previously Presented) A composition, comprising the polypeptide, derivative or analogue thereof according to claim 1.

Claim 9 (Canceled).

10. (Withdrawn) A method of preventing and/or treating a viral infection, comprising administering to a subject in need of treatment a therapeutically effective amount of the polypeptide, derivative or analogue according to claim 1.
11. (Withdrawn) An agent adapted to increase the biological activity of the polypeptide, derivative or analogue according to claim 1.

Claim 12 (Canceled).

13. (Withdrawn) A nucleic acid sequence encoding the polypeptide, derivative or analogue according to claim 1.
14. (Withdrawn) A composition, comprising the nucleic acid according to claim 13.

Claim 15 (Canceled).

16. (Withdrawn) The nucleic acid according to claim 13, wherein the nucleic acid comprises a nucleotide sequence as set out as SEQ ID No.8 (apoB3359-3367), SEQ ID No.9 (GIN 16), SEQ ID No.10 (GIN 35), SEQ ID No.11 (GIN 36), SEQ ID No.12 (GIN 37), SEQ ID No.13 (GIN 38), or SEQ ID No.14 (GIN 33).
17. (Withdrawn) A method of preventing and/or treating a viral infection, comprising administering to a subject in need of treatment a therapeutically effective amount of the nucleic acid according to claim 13.
18. (Previously Presented) The polypeptide, derivative or analogue thereof according to claim 4, wherein at least one of the first, second, third, seventh, eighth, ninth, tenth, eleventh, twelfth, sixteenth, seventeenth or eighteenth residues is substituted or deleted.